Gino Santini is on the board of ImClone LLC and 7 other companies. Mr. Santini previously occupied the position of Senior VP-Business Development & Strategy at Eli Lilly & Co. and General Manager for Eli Lilly y CIA de México SA de CV (a subsidiary of Eli Lilly & Co.), Chairman for AMAG Pharmaceuticals, Inc., Chairman at National Pharmaceutical Council and Chairman at Noble of Indiana.
He received an undergraduate degree from Alma Mater Studiorum - Università di Bologna and an MBA from the University of Rochester Simon Business School.
|04/29/2022||1,658||Derivative/Non-derivative trans. at $98.56 per share.||163,413|
|04/29/2022||4,223||Derivative/Non-derivative trans. at $0 per share.||0|
|04/30/2021||4,357||Derivative/Non-derivative trans. at $94.62 per share.||412,260|
|04/30/2021||11,098||Derivative/Non-derivative trans. at $0 per share.||0|
|03/01/2021||12,000||Disposition at $91.47 per share.||1,097,640|
|08/03/2020||20,000||Derivative/Non-derivative trans. at $2.37 per share.||47,400|
|08/03/2020||5,265||Derivative/Non-derivative trans. at $3.95 per share.||20,796|
|08/03/2020||10,530||Derivative/Non-derivative trans. at $3.33 per share.||35,064|
|05/02/2020||6,041||Derivative/Non-derivative trans. at $35.62 per share.||215,181|
|05/02/2020||15,390||Derivative/Non-derivative trans. at $0 per share.||0|
|05/03/2019||6,014||Derivative/Non-derivative trans. at $26.54 per share.||159,612|
|05/03/2019||15,320||Derivative/Non-derivative trans. at $0 per share.||0|
|05/03/2018||5,517||Derivative/Non-derivative trans. at $13.87 per share.||76,521|
|05/03/2018||14,054||Derivative/Non-derivative trans. at $0 per share.||0|